Cambridge Innovation Capital has returned for a series C round for University of Cambridge-linked Gyroscope Therapeutics, which also welcomed back Syncona.
Gyroscope Therapeutics, the UK-based developer of retinal disease treatments based partly on University of Cambridge research, pocketed $148m in a series C round today backed by patient capital fund Cambridge Innovation Capital (CIC).
Syncona, the life sciences investment trust backed by research charities Wellcome Trust and Cancer Research UK, also took part in the round, which was led by Forbion’s Growth Opportunities Fund.
Pharmaceutical firm Fosun Pharma, Sofinnova Investments, Tetragon Financial Group and an unnamed healthcare-focused fund filled…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
